COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+
Adverse events were primarily mild, and no serious adverse events (SAEs) were noted
Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up
No cases of myocarditis or blood clots were reported, as expected with inactivated vaccines
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.